Your browser doesn't support javascript.
loading
Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus.
Migita, Kiyoshi; Akeda, Yukihiro; Akazawa, Manabu; Tohma, Shigeto; Hirano, Fuminori; Ideguchi, Haruko; Matsumura, Ryutaro; Suematsu, Eiichi; Miyamura, Tomoya; Mori, Shunsuke; Fukui, Takahiro; Izumi, Yasumori; Iwanaga, Nozomi; Tsutani, Hiroshi; Saisyo, Kouichirou; Yamanaka, Takao; Ohshima, Shiro; Sugiyama, Takao; Kawabe, Yojiro; Katayama, Masao; Suenaga, Yasuo; Okamoto, Akira; Ohshima, Hisaji; Okada, Yasumasa; Ichikawa, Kenji; Yoshizawa, Shigeru; Kawakami, Kenji; Matsui, Toshihiro; Furukawa, Hiroshi; Oishi, Kazunori.
Afiliación
  • Migita K; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. migita@nagasaki-mc.com.
  • Akeda Y; Clinical Research Center, NHO Nagasaki Medical Center, Kubara 2-1001-1, Omura, 856-8652, Japan. migita@nagasaki-mc.com.
  • Akazawa M; Research Institute for Microbial Diseases, Osaka University, Yamadaoka 3-1, Suita, Osaka, 565-8563, Japan. akeda@biken.osaka-u.ac.jp.
  • Tohma S; Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Noshio 2-522-1, Kiyose, Tokyo, 204-8588, Japan. makazawa@my-pharm.ac.jp.
  • Hirano F; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. s-touma@sagamihara-hosp.gr.jp.
  • Ideguchi H; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. hirano@asahikawa.hosp.go.jp.
  • Matsumura R; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. ideguchi@cronos.ocn.ne.jp.
  • Suematsu E; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. ryu-ma@cehpnet.com.
  • Miyamura T; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. suematsu@qmed.hosp.go.jp.
  • Mori S; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. miyamura@kyumed.jp.
  • Fukui T; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. moris@saisyunsou1.hosp.go.jp.
  • Izumi Y; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. opmeisterf@yahoo.co.jp.
  • Iwanaga N; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. yizumi@nagasaki-mc.com.
  • Tsutani H; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. n.iwanaga@nagasaki-mc.com.
  • Saisyo K; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. htsutani@kitagata.hosp.go.jp.
  • Yamanaka T; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. saisyo@miyakonojo.hosp.go.jp.
  • Ohshima S; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. yamanaka.takao@momc.jp.
  • Sugiyama T; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. ohshimas@ommc-hp.jp.
  • Kawabe Y; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. sugiyama@simosizu2.hosp.go.jp.
  • Katayama M; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. ykawabe@uresino.go.jp.
  • Suenaga Y; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. katayamm@nnh.hosp.go.jp.
  • Okamoto A; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. rheuma@beppu.hosp.go.jp.
  • Ohshima H; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. aokamoto@hmj-net.hosp.go.jp.
  • Okada Y; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. HOhshima@ntmc.hosp.go.jp.
  • Ichikawa K; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. yasumasaokada@1979.jukuin.keio.ac.jp.
  • Yoshizawa S; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. k-ichika@hok-mc.hosp.go.jp.
  • Kawakami K; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. syoshi@mfukuoka2.hosp.go.jp.
  • Matsui T; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. kkawakami@nkmc1.jp.
  • Furukawa H; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. t-matsui@sagamihara-hosp.gr.jp.
  • Oishi K; Japanese National Hospital Organization (NHO, EBM study group), Higashigaoka 2-5-23, Meguro, Tokyo, 152-8621, Japan. h-furukawa@sagamihara-hosp.gr.jp.
Arthritis Res Ther ; 17: 149, 2015 Jun 03.
Article en En | MEDLINE | ID: mdl-26036592
ABSTRACT

INTRODUCTION:

In rheumatoid arthritis (RA) patients receiving immunosuppressive treatments, vaccination against Streptococcus pneumoniae is recommended. The objective of the study was to evaluate the effects of tacrolimus (TAC) on immune response following administration of a 23-valent pneumococcal polysaccharide vaccine (PPSV23) in patients with established RA.

METHODS:

Patients with RA (n = 133) were vaccinated with PPSV23. Patients were classified into TAC (n = 29), methotrexate (MTX) (n = 55), control (n = 35), and TAC/MTX (n = 14) treatment groups. We measured the concentrations of pneumococcal serotypes 6B and 23F by using an enzyme-linked immunosorbent assay and determined antibody functionality by using a multiplexed opsonophagocytic killing assay, reported as the opsonization index (OI), before and 4 to 6 weeks after vaccination. A positive antibody response was defined as at least a twofold increase in the IgG concentration or as at least a 10-fold increase in the OI.

RESULTS:

IgG concentrations and OIs were significantly increased in all treatment groups after PPSV23 vaccination. The TAC treatment group appears to respond in a manner similar to that of the RA control group in terms of 6B and 23F serotype concentration and function. In contrast, the MTX group had the lowest immune response. Patients who received a combination of TAC and MTX (TAC/MTX) also had a diminished immune response compared with those who received TAC alone.

CONCLUSIONS:

TAC monotherapy does not appear to impair PPSV23 immunogenicity in patients with RA, whereas antibody production and function may be reduced when TAC is used with MTX. Thus, PPSV23 administration during ongoing TAC treatment should be encouraged for infection-prone TAC-treated patients with rheumatic diseases. TRIAL REGISTRATION University Hospital Medical Information Network Clinical Trials Registry UMIN000009566. Registered 12 December 2012.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Artritis Reumatoide / Tacrolimus / Antirreumáticos / Vacunas Neumococicas / Anticuerpos Antibacterianos Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Arthritis Res Ther Asunto de la revista: REUMATOLOGIA Año: 2015 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Artritis Reumatoide / Tacrolimus / Antirreumáticos / Vacunas Neumococicas / Anticuerpos Antibacterianos Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Arthritis Res Ther Asunto de la revista: REUMATOLOGIA Año: 2015 Tipo del documento: Article País de afiliación: Japón